Bexarotene-d4 is a deuterated form of the synthetic retinoid bexarotene, primarily used in the treatment of certain types of cancer, particularly cutaneous T-cell lymphoma. The "d4" designation indicates that four hydrogen atoms in the molecule have been replaced with deuterium, a stable isotope of hydrogen, which can be useful in research applications, particularly in pharmacokinetics and metabolic studies. Bexarotene functions as a selective agonist for retinoid X receptors (RXRs), influencing gene expression and cellular differentiation. Its chemical structure includes a bicyclic core that is characteristic of retinoids, contributing to its biological activity. The deuterated version may exhibit altered pharmacokinetic properties compared to its non-deuterated counterpart, potentially affecting its absorption, distribution, metabolism, and excretion. As with other retinoids, the use of bexarotene-d4 may be associated with side effects, and its therapeutic applications are typically guided by clinical considerations and ongoing research.

Bexarotene-d4

2182068-00-2: Bexarotene-d4 is a deuterated form of the synthetic retinoid bexarotene, primarily used in the treatment of certain types of cancer, particularly cutaneous T-cell lymphoma. The "d4" designation indicates that four hydrogen atoms in the molecule have been replaced with deuterium, a stable isotope of hydrogen, which can be useful in research applications, particularly in pharmacokinetics and metabolic studies. Bexarotene functions as a selective agonist for retinoid X receptors (RXRs), influencing gene expression and cellular differentiation. Its chemical structure includes a bicyclic core that is characteristic of retinoids, contributing to its biological activity. The deuterated version may exhibit altered pharmacokinetic properties compared to its non-deuterated counterpart, potentially affecting its absorption, distribution, metabolism, and excretion. As with other retinoids, the use of bexarotene-d4 may be associated with side effects, and its therapeutic applications are typically guided by clinical considerations and ongoing research.

<p>Bexarotene D4 is a deuterium-labeled Bexarotene (LGD1069). Bexarotene is a selective RXR agonist used in the treatment of cutaneous T-cell lymphoma.</p>

CAS 2182068-00-2

Bexarotene-d4

Bexarotene D4

Ref: TM-T10528